Ottewell P - Search Results

1

Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts.

Lefley D, Howard F, Arshad F, Bradbury S, Brown H, Tulotta C, Eyre R, Alférez D, Wilkinson JM, Holen I, Clarke RB, Ottewell P. Lefley D, et al. Among authors: ottewell p. Breast Cancer Res. 2019 Nov 29;21(1):130. doi: 10.1186/s13058-019-1220-2. Breast Cancer Res. 2019. PMID: 31783893 Free PMC article.

2

From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies.

Ottewell PD, Coleman RE, Holen I. Ottewell PD, et al. Breast Cancer Res Treat. 2006 Mar;96(2):101-13. doi: 10.1007/s10549-005-9067-x. Breast Cancer Res Treat. 2006. PMID: 16319986 Review.

3

Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.

Ottewell PD, Deux B, Mönkkönen H, Cross S, Coleman RE, Clezardin P, Holen I. Ottewell PD, et al. Clin Cancer Res. 2008 Jul 15;14(14):4658-66. doi: 10.1158/1078-0432.CCR-07-1545. Clin Cancer Res. 2008. PMID: 18628481

4

Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE, Holen I. Ottewell PD, et al. J Natl Cancer Inst. 2008 Aug 20;100(16):1167-78. doi: 10.1093/jnci/djn240. Epub 2008 Aug 11. J Natl Cancer Inst. 2008. PMID: 18695136

5

Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model.

Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE, Holen I. Ottewell PD, et al. Int J Cancer. 2010 Jan 15;126(2):522-32. doi: 10.1002/ijc.24756. Int J Cancer. 2010. PMID: 19621384

6

Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.

Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, Holen I. Ottewell PD, et al. Mol Cancer Ther. 2009 Oct;8(10):2821-32. doi: 10.1158/1535-7163.MCT-09-0462. Epub 2009 Sep 29. Mol Cancer Ther. 2009. PMID: 19789217

7

The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells.

Brown HK, Ottewell PD, Coleman RE, Holen I. Brown HK, et al. J Cell Mol Med. 2011 Mar;15(3):501-13. doi: 10.1111/j.1582-4934.2009.00995.x. J Cell Mol Med. 2011. PMID: 20015195 Free PMC article.

8

Combined therapies of bone disease with bisphosphonates.

Syddall SP, Ottewell PD, Holen I. Syddall SP, et al. Among authors: ottewell pd. Curr Pharm Des. 2010;16(27):2988-97. doi: 10.2174/138161210793563590. Curr Pharm Des. 2010. PMID: 20722617 Review.

9

Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice.

Ottewell PD, Brown HK, Jones M, Rogers TL, Cross SS, Brown NJ, Coleman RE, Holen I. Ottewell PD, et al. Breast Cancer Res Treat. 2012 Jun;133(2):523-36. doi: 10.1007/s10549-011-1782-x. Epub 2011 Sep 29. Breast Cancer Res Treat. 2012. PMID: 21956211

10

Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo.

Brown HK, Ottewell PD, Evans CA, Holen I. Brown HK, et al. Among authors: ottewell pd. Clin Exp Metastasis. 2012 Dec;29(8):927-38. doi: 10.1007/s10585-012-9481-5. Epub 2012 May 6. Clin Exp Metastasis. 2012. PMID: 22562502

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

64 results

Search Page

Filters